TauroPharm

TauroPace™ sets a new standard for the prevention of infections from cardiac implantable electronic devices: https://t.ly/ehm7S #tauropharm #tauropace #infectionprevention #cardiology #cardiacsurgery #heartsurgery #pacemaker

'Tis the season … to bake TauroLock™-shaped cookies! 🍪🎄 No taurolidine used for this recipe though. 🫡 How do you think our creation turned out? Thank you Tauro-Implant GmbH for the cookie cutters! ✨ #tauropharm #taurolock

'Tis the season … to bake TauroLock™-shaped cookies! 🍪🎄 No taurolidine used for this recipe though. 🫡 How do you think our creation turned out? Thank you Tauro-Implant GmbH for the cookie cutters! ✨ #tauropharm #taurolock

2024. I wanted to post something about my highlights of the year with TauroPharm . But then I looked at my calendar and realized that there are too many highlights to list them all. A very nice problem to have!   So, here is a very short summary (with a lot of highlights left out):   The annual meeting of the European Heart Rhythm Association (EHRA) took place in Berlin this year. It was a great opportunity to present TauroPace™ to a large number of specialists in the field.   A few days later, I flew from Frankfurt to Buenos Aires for the World Congress of Nephrology (WCN). One of the most important occasions where we can discuss TauroLock™ products with leading nephrologists from around the world. I have attended this congress many times and it’s always worth the trip (even just because of the beautiful cities where it takes place!).  In November, we had another event on our home turf in Germany: The MEDICA in Düsseldorf. So many of our partners were there, we had a great time.   Last but not least: Our new conference room near our headquarters in Waldbüttelbrunn was finally opened this year. We already had several workshops there with our partners from Germany, Switzerland, Austria, Czechia, Slovakia, UK, Ireland, and Bahrain. There will be many more in 2025!   I wish everyone a peaceful holiday season and a healthy start into the new year.   Frohes Fest und guten Rutsch!

Addio alle complicazioni legate al catetere! 🇮🇹 What do Italian expert panels recommend for preventing catheter-related complications? There seems to be one common denominator... 👇 "…𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘢𝘱𝘱𝘳𝘰𝘱𝘳𝘪𝘢𝘵𝘦 𝘭𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘴𝘩𝘰𝘶𝘭𝘥 𝘪𝘯𝘤𝘭𝘶𝘥𝘦 𝘤𝘪𝘵𝘳𝘢𝘵𝘦 𝘢𝘯𝘥/𝘰𝘳 𝙩𝙖𝙪𝙧𝙤𝙡𝙞𝙙𝙞𝙣𝙚, 𝘸𝘩𝘪𝘤𝘩 𝘩𝘢𝘷𝘦 𝘣𝘰𝘵𝘩 𝘢𝘯𝘵𝘪-𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘢𝘯𝘥 𝘢𝘯𝘵𝘪-𝘣𝘪𝘰𝘧𝘪𝘭𝘮 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺, 𝘸𝘪𝘵𝘩 𝘯𝘦𝘨𝘭𝘪𝘨𝘪𝘣𝘭𝘦 𝘶𝘯𝘥𝘦𝘴𝘪𝘳𝘦𝘥 𝘦𝘧𝘧𝘦𝘤𝘵𝘴 𝘪𝘧 𝘤𝘰𝘮𝘱𝘢𝘳𝘦𝘥 𝘵𝘰 𝘢𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤𝘴…" (1) “𝘓𝘰𝘤𝘬𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘯𝘰𝘯-𝘢𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤 𝘢𝘯𝘵𝘪𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘴𝘶𝘣𝘴𝘵𝘢𝘯𝘤𝘦𝘴 (𝘪𝘯 𝘱𝘢𝘳𝘵𝘪𝘤𝘶𝘭𝘢𝘳, 2% 𝙩𝙖𝙪𝙧𝙤𝙡𝙞𝙙𝙞𝙣𝙚) 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘱𝘳𝘰𝘷𝘦𝘯 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘪𝘯 𝘱𝘦𝘥𝘪𝘢𝘵𝘳𝘪𝘤 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘳𝘦𝘥𝘶𝘤𝘪𝘯𝘨 𝘵𝘩𝘦 𝘳𝘪𝘴𝘬 𝘰𝘧 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯.” (2) “𝙏𝙖𝙪𝙧𝙤𝙡𝙞𝙙𝙞𝙣𝙚 𝘭𝘰𝘤𝘬 𝘪𝘴 𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘭𝘺 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘧𝘰𝘳 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘪𝘯 𝘰𝘶𝘵𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘮𝘦𝘥𝘪𝘶𝘮-𝘭𝘰𝘯𝘨 𝘵𝘦𝘳𝘮 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘝𝘈𝘋𝘴...” (3) 💡 If you’d like to know more about the use of taurolidine-based lock solutions in Italy, our parters at Medival S.r.l. are happy to help! #tauropharm #taurolock #taurolidine #infectionprevention 1) Pittiruti et al. J Vasc Access 2016. DOI: 10.5301/jva.5000576  2) Cellini et al. J Vasc Access 2022. DOI: 10.1177/1129729820969309  3) Pinelli et al. J Vasc Access 2024. DOI: 10.1177/11297298241262932 

Addio alle complicazioni legate al catetere! 🇮🇹 What do Italian expert panels recommend for preventing catheter-related complications? There seems to be one common denominator... 👇 "…𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘢𝘱𝘱𝘳𝘰𝘱𝘳𝘪𝘢𝘵𝘦 𝘭𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘴𝘩𝘰𝘶𝘭𝘥 𝘪𝘯𝘤𝘭𝘶𝘥𝘦 𝘤𝘪𝘵𝘳𝘢𝘵𝘦 𝘢𝘯𝘥/𝘰𝘳 𝙩𝙖𝙪𝙧𝙤𝙡𝙞𝙙𝙞𝙣𝙚, 𝘸𝘩𝘪𝘤𝘩 𝘩𝘢𝘷𝘦 𝘣𝘰𝘵𝘩 𝘢𝘯𝘵𝘪-𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘢𝘯𝘥 𝘢𝘯𝘵𝘪-𝘣𝘪𝘰𝘧𝘪𝘭𝘮 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺, 𝘸𝘪𝘵𝘩 𝘯𝘦𝘨𝘭𝘪𝘨𝘪𝘣𝘭𝘦 𝘶𝘯𝘥𝘦𝘴𝘪𝘳𝘦𝘥 𝘦𝘧𝘧𝘦𝘤𝘵𝘴 𝘪𝘧 𝘤𝘰𝘮𝘱𝘢𝘳𝘦𝘥 𝘵𝘰 𝘢𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤𝘴…" (1) “𝘓𝘰𝘤𝘬𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘯𝘰𝘯-𝘢𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤 𝘢𝘯𝘵𝘪𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘴𝘶𝘣𝘴𝘵𝘢𝘯𝘤𝘦𝘴 (𝘪𝘯 𝘱𝘢𝘳𝘵𝘪𝘤𝘶𝘭𝘢𝘳, 2% 𝙩𝙖𝙪𝙧𝙤𝙡𝙞𝙙𝙞𝙣𝙚) 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘱𝘳𝘰𝘷𝘦𝘯 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘪𝘯 𝘱𝘦𝘥𝘪𝘢𝘵𝘳𝘪𝘤 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘳𝘦𝘥𝘶𝘤𝘪𝘯𝘨 𝘵𝘩𝘦 𝘳𝘪𝘴𝘬 𝘰𝘧 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯.” (2) “𝙏𝙖𝙪𝙧𝙤𝙡𝙞𝙙𝙞𝙣𝙚 𝘭𝘰𝘤𝘬 𝘪𝘴 𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘭𝘺 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘧𝘰𝘳 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘪𝘯 𝘰𝘶𝘵𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘮𝘦𝘥𝘪𝘶𝘮-𝘭𝘰𝘯𝘨 𝘵𝘦𝘳𝘮 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘝𝘈𝘋𝘴...” (3) 💡 If you’d like to know more about the use of taurolidine-based lock solutions in Italy, our parters at Medival S.r.l. are happy to help! #tauropharm #taurolock #taurolidine #infectionprevention 1) Pittiruti et al. J Vasc Access 2016. DOI: 10.5301/jva.5000576  2) Cellini et al. J Vasc Access 2022. DOI: 10.1177/1129729820969309  3) Pinelli et al. J Vasc Access 2024. DOI: 10.1177/11297298241262932 

What do 𝗚𝗲𝗿𝗺𝗮𝗻 𝗲𝘅𝗽𝗲𝗿𝘁 𝗽𝗮𝗻𝗲𝗹𝘀 have to say about taurolidine in lock solutions? ☝️ A lot indeed! In recent years, more and more guidelines have added an explicit mention of the antimicrobial agent. Here’s an overview of 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀 (among others), sorted by field of application:  𝗗𝗶𝗮𝗹𝘆𝘀𝗶𝘀 “𝘔𝘦𝘵𝘢-𝘢𝘯𝘢𝘭𝘺𝘴𝘦𝘴 𝘤𝘰𝘯𝘧𝘪𝘳𝘮 𝘵𝘩𝘦 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺 𝘰𝘧 𝘤𝘪𝘵𝘳𝘢𝘵𝘦 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘴𝘶𝘱𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘦𝘥 𝘣𝘺 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘵𝘪𝘮𝘪𝘤𝘳𝘰𝘣𝘪𝘢𝘭 𝘪𝘯𝘨𝘳𝘦𝘥𝘪𝘦𝘯𝘵𝘴 (𝘦.𝘨. 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦).” (1)    𝗣𝗮𝗿𝗲𝗻𝘁𝗲𝗿𝗮𝗹 𝗻𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻 “𝘛𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦-𝘣𝘢𝘴𝘦𝘥 𝘭𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘴𝘩𝘰𝘶𝘭𝘥 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘵𝘰 𝘳𝘦𝘥𝘶𝘤𝘦 𝘵𝘩𝘦 𝘳𝘪𝘴𝘬 𝘰𝘧 𝘊𝘙𝘉𝘚𝘐 𝘪𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘵 𝘩𝘪𝘨𝘩 𝘳𝘪𝘴𝘬; 𝘪𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘵 𝘯𝘰𝘳𝘮𝘢𝘭 𝘳𝘪𝘴𝘬, 𝘵𝘩𝘦𝘺 𝘴𝘩𝘰𝘶𝘭𝘥 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘢𝘴 𝘢𝘯 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘵𝘰 𝘱𝘳𝘦𝘷𝘦𝘯𝘵 𝘊𝘙𝘉𝘚𝘐.” (2)    𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆  “𝘓𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘪𝘯𝘨 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦 𝘢𝘳𝘦 𝘳𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥𝘦𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘰𝘧 𝘊𝘝𝘈𝘋-𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯𝘴 (𝘊𝘢𝘵. 𝘐𝘉).” (3)    𝗜𝗖𝗨 “𝘐𝘯 𝘤𝘢𝘴𝘦 𝘰𝘧 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘯𝘰𝘵 𝘰𝘯𝘭𝘺 𝘵𝘦𝘮𝘱𝘰𝘳𝘢𝘳𝘺 (𝘦.𝘨. 𝘱𝘰𝘴𝘵𝘰𝘱𝘦𝘳𝘢𝘵𝘪𝘷𝘦) 𝘤𝘺𝘤𝘭𝘪𝘤𝘢𝘭 𝘱𝘢𝘳𝘦𝘯𝘵𝘦𝘳𝘢𝘭 𝘯𝘶𝘵𝘳𝘪𝘵𝘪𝘰𝘯 𝘰𝘷𝘦𝘳 𝘢 𝘤𝘰𝘯𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘢𝘭, 𝘯𝘰𝘯-𝘵𝘶𝘯𝘯𝘦𝘭𝘭𝘦𝘥 𝘊𝘝𝘊, 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘳𝘮𝘪𝘵𝘵𝘦𝘯𝘵 𝘣𝘭𝘰𝘤𝘬𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦... 𝘮𝘢𝘺 𝘣𝘦 𝘤𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘦𝘥…” (4) #tauropharm #taurolock #dialysis #parenteralnutrition #oncology #icu    1) German Society for Applied Hygiene in Dialysis (DGfaHD) 2022.  2) German Society for Clinical Nutrition and Metabolism (DGEM) in cooperation with AKE/GESKES/DGP 2024. DOI: 10.1055/a-2270-7667  3) Society for Paediatric Oncology and Haematology (GPOH) 2018.  4) Commission for Hospital Hygiene and Infection Prevention (KRINKO) at Robert Koch Institute 2017. DOI: 10.1007/s00103-016-2487-4 

What do 𝗚𝗲𝗿𝗺𝗮𝗻 𝗲𝘅𝗽𝗲𝗿𝘁 𝗽𝗮𝗻𝗲𝗹𝘀 have to say about taurolidine in lock solutions? ☝️ A lot indeed! In recent years, more and more guidelines have added an explicit mention of the antimicrobial agent. Here’s an overview of 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀 (among others), sorted by field of application:  𝗗𝗶𝗮𝗹𝘆𝘀𝗶𝘀 “𝘔𝘦𝘵𝘢-𝘢𝘯𝘢𝘭𝘺𝘴𝘦𝘴 𝘤𝘰𝘯𝘧𝘪𝘳𝘮 𝘵𝘩𝘦 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺 𝘰𝘧 𝘤𝘪𝘵𝘳𝘢𝘵𝘦 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘴𝘶𝘱𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘦𝘥 𝘣𝘺 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘵𝘪𝘮𝘪𝘤𝘳𝘰𝘣𝘪𝘢𝘭 𝘪𝘯𝘨𝘳𝘦𝘥𝘪𝘦𝘯𝘵𝘴 (𝘦.𝘨. 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦).” (1)    𝗣𝗮𝗿𝗲𝗻𝘁𝗲𝗿𝗮𝗹 𝗻𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻 “𝘛𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦-𝘣𝘢𝘴𝘦𝘥 𝘭𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘴𝘩𝘰𝘶𝘭𝘥 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘵𝘰 𝘳𝘦𝘥𝘶𝘤𝘦 𝘵𝘩𝘦 𝘳𝘪𝘴𝘬 𝘰𝘧 𝘊𝘙𝘉𝘚𝘐 𝘪𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘵 𝘩𝘪𝘨𝘩 𝘳𝘪𝘴𝘬; 𝘪𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘵 𝘯𝘰𝘳𝘮𝘢𝘭 𝘳𝘪𝘴𝘬, 𝘵𝘩𝘦𝘺 𝘴𝘩𝘰𝘶𝘭𝘥 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘢𝘴 𝘢𝘯 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘵𝘰 𝘱𝘳𝘦𝘷𝘦𝘯𝘵 𝘊𝘙𝘉𝘚𝘐.” (2)    𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆  “𝘓𝘰𝘤𝘬 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘪𝘯𝘨 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦 𝘢𝘳𝘦 𝘳𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥𝘦𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘰𝘧 𝘊𝘝𝘈𝘋-𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘪𝘯𝘧𝘦𝘤𝘵𝘪𝘰𝘯𝘴 (𝘊𝘢𝘵. 𝘐𝘉).” (3)    𝗜𝗖𝗨 “𝘐𝘯 𝘤𝘢𝘴𝘦 𝘰𝘧 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘯𝘰𝘵 𝘰𝘯𝘭𝘺 𝘵𝘦𝘮𝘱𝘰𝘳𝘢𝘳𝘺 (𝘦.𝘨. 𝘱𝘰𝘴𝘵𝘰𝘱𝘦𝘳𝘢𝘵𝘪𝘷𝘦) 𝘤𝘺𝘤𝘭𝘪𝘤𝘢𝘭 𝘱𝘢𝘳𝘦𝘯𝘵𝘦𝘳𝘢𝘭 𝘯𝘶𝘵𝘳𝘪𝘵𝘪𝘰𝘯 𝘰𝘷𝘦𝘳 𝘢 𝘤𝘰𝘯𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘢𝘭, 𝘯𝘰𝘯-𝘵𝘶𝘯𝘯𝘦𝘭𝘭𝘦𝘥 𝘊𝘝𝘊, 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘳𝘮𝘪𝘵𝘵𝘦𝘯𝘵 𝘣𝘭𝘰𝘤𝘬𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘵𝘢𝘶𝘳𝘰𝘭𝘪𝘥𝘪𝘯𝘦... 𝘮𝘢𝘺 𝘣𝘦 𝘤𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘦𝘥…” (4) #tauropharm #taurolock #dialysis #parenteralnutrition #oncology #icu    1) German Society for Applied Hygiene in Dialysis (DGfaHD) 2022.  2) German Society for Clinical Nutrition and Metabolism (DGEM) in cooperation with AKE/GESKES/DGP 2024. DOI: 10.1055/a-2270-7667  3) Society for Paediatric Oncology and Haematology (GPOH) 2018.  4) Commission for Hospital Hygiene and Infection Prevention (KRINKO) at Robert Koch Institute 2017. DOI: 10.1007/s00103-016-2487-4 

𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗶𝘀 𝗯𝗲𝘁𝘁𝗲𝗿 𝘁𝗵𝗮𝗻 𝗰𝘂𝗿𝗲 – 𝗲𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗹𝘆 𝗶𝗻 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻 𝘄𝗶𝘁𝗵 𝗰𝗮𝗻𝗰𝗲𝗿. This became (once again) obvious during a clinical study conducted at the Institute of Paediatric Oncology and Haematology in Moscow. ➡️ From 2010 to 2015, 186 patients aged between 2 months and 17 years were observed. All patients received chemotherapy through an implantable venous port system (IVPS). 🔹The patients were divided in several groups using different lock solutions: Saline only, saline with a minimal amount of heparin, or TauroLock™.  🔹𝗡𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘂𝘀𝗶𝗻𝗴 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ (𝟲𝟰 𝗶𝗻 𝘁𝗼𝘁𝗮𝗹) 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗮 𝗖𝗥𝗕𝗦𝗜.  🔹Among the patients who did not use TauroLock™ (122 in total), 10 developed a CRBSI.   🔹𝗜𝗻 𝟵 𝗼𝘂𝘁 𝗼𝗳 𝟭𝟬 𝗰𝗮𝘀𝗲𝘀, 𝗖𝗥𝗕𝗦𝗜 𝘄𝗲𝗿𝗲 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹𝗹𝘆 𝘁𝗿𝗲𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™.   🔹52 patients developed thrombosis. In 47 of these (90.4 %), the patency was successfully restored with TauroLock™-U25.000. The authors concluded that 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ 𝗮𝗻𝗱 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™-𝗨𝟮𝟱.𝟬𝟬𝟬 “𝘀𝗵𝗼𝘄𝗲𝗱 𝘁𝗵𝗲𝗶𝗿 𝗵𝗶𝗴𝗵 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝗶𝗻 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗖𝗥𝗕𝗦𝗜 𝗮𝗻𝗱 𝗰𝗮𝘁𝗵𝗲𝘁𝗲𝗿 𝘁𝗵𝗿𝗼𝗺𝗯𝗼𝘀𝗶𝘀” and therefore recommended them “for wide administration in clinics dealing with the treatment of cancer patients”.  💡 What’s our take-away from these findings? We are pleased to see that our products proved effective in treating catheter-related complications in 90 % of affected patients. Yet the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗿𝗮𝘁𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝘃𝗲 𝘂𝘀𝗲 𝗼𝗳 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ 𝘄𝗮𝘀 𝗲𝘃𝗲𝗻 𝗵𝗶𝗴𝗵𝗲𝗿: 0 CRBSI in 64 patients.  𝙒𝙝𝙮 𝙬𝙖𝙞𝙩 𝙪𝙣𝙩𝙞𝙡 𝙞𝙩’𝙨 𝙩𝙤𝙤 𝙡𝙖𝙩𝙚 𝙬𝙝𝙚𝙣 𝙮𝙤𝙪 𝙘𝙖𝙣 𝙥𝙧𝙤𝙩𝙚𝙘𝙩 𝙫𝙪𝙡𝙣𝙚𝙧𝙖𝙗𝙡𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙛𝙧𝙤𝙢 𝙩𝙝𝙚 𝙫𝙚𝙧𝙮 𝙨𝙩𝙖𝙧𝙩?   Source: Rykov et al. Oncopediatrics 2016. DOI: 10.15690/ONCO.V3I3.1601 #tauropharm #taurolock #oncology #cancer #infectionprevention #chemotherapy 

𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗶𝘀 𝗯𝗲𝘁𝘁𝗲𝗿 𝘁𝗵𝗮𝗻 𝗰𝘂𝗿𝗲 – 𝗲𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗹𝘆 𝗶𝗻 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻 𝘄𝗶𝘁𝗵 𝗰𝗮𝗻𝗰𝗲𝗿. This became (once again) obvious during a clinical study conducted at the Institute of Paediatric Oncology and Haematology in Moscow. ➡️ From 2010 to 2015, 186 patients aged between 2 months and 17 years were observed. All patients received chemotherapy through an implantable venous port system (IVPS). 🔹The patients were divided in several groups using different lock solutions: Saline only, saline with a minimal amount of heparin, or TauroLock™.  🔹𝗡𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘂𝘀𝗶𝗻𝗴 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ (𝟲𝟰 𝗶𝗻 𝘁𝗼𝘁𝗮𝗹) 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗮 𝗖𝗥𝗕𝗦𝗜.  🔹Among the patients who did not use TauroLock™ (122 in total), 10 developed a CRBSI.   🔹𝗜𝗻 𝟵 𝗼𝘂𝘁 𝗼𝗳 𝟭𝟬 𝗰𝗮𝘀𝗲𝘀, 𝗖𝗥𝗕𝗦𝗜 𝘄𝗲𝗿𝗲 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹𝗹𝘆 𝘁𝗿𝗲𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™.   🔹52 patients developed thrombosis. In 47 of these (90.4 %), the patency was successfully restored with TauroLock™-U25.000. The authors concluded that 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ 𝗮𝗻𝗱 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™-𝗨𝟮𝟱.𝟬𝟬𝟬 “𝘀𝗵𝗼𝘄𝗲𝗱 𝘁𝗵𝗲𝗶𝗿 𝗵𝗶𝗴𝗵 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝗶𝗻 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗖𝗥𝗕𝗦𝗜 𝗮𝗻𝗱 𝗰𝗮𝘁𝗵𝗲𝘁𝗲𝗿 𝘁𝗵𝗿𝗼𝗺𝗯𝗼𝘀𝗶𝘀” and therefore recommended them “for wide administration in clinics dealing with the treatment of cancer patients”.  💡 What’s our take-away from these findings? We are pleased to see that our products proved effective in treating catheter-related complications in 90 % of affected patients. Yet the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗿𝗮𝘁𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝘃𝗲 𝘂𝘀𝗲 𝗼𝗳 𝗧𝗮𝘂𝗿𝗼𝗟𝗼𝗰𝗸™ 𝘄𝗮𝘀 𝗲𝘃𝗲𝗻 𝗵𝗶𝗴𝗵𝗲𝗿: 0 CRBSI in 64 patients.  𝙒𝙝𝙮 𝙬𝙖𝙞𝙩 𝙪𝙣𝙩𝙞𝙡 𝙞𝙩’𝙨 𝙩𝙤𝙤 𝙡𝙖𝙩𝙚 𝙬𝙝𝙚𝙣 𝙮𝙤𝙪 𝙘𝙖𝙣 𝙥𝙧𝙤𝙩𝙚𝙘𝙩 𝙫𝙪𝙡𝙣𝙚𝙧𝙖𝙗𝙡𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙛𝙧𝙤𝙢 𝙩𝙝𝙚 𝙫𝙚𝙧𝙮 𝙨𝙩𝙖𝙧𝙩?   Source: Rykov et al. Oncopediatrics 2016. DOI: 10.15690/ONCO.V3I3.1601 #tauropharm #taurolock #oncology #cancer #infectionprevention #chemotherapy